Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

Pfizer is set to enter the heated VEGF bispecific arena. Much like its peers, the New York drug giant is doing so by going to China in the battle for one of oncology's hottest classes ...